在急性心肌梗塞中识别与cuproptosis相关的潜在生物标志物和免疫微环境分析:一种诊断准确性研究

相关实验视频

Updated: May 30, 2025

Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease

Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease

Published on: July 3, 2018

Jing Zhang¹, Zhijie Yue¹, Na Zhu²

¹Department of Cardiovascular Internal Medicine, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Third Hospital of Shanxi Medical University, Taiyuan, China.

|January 31, 2025

概括

这项研究确定了五个关键生物标志物,这些生物标志物与 cuproptosis 相关,这是一种涉及铜的细胞死亡过程,在急性心肌梗塞 (AMI) 中. 这些发现为心脏病发作患者的潜在诊断和治疗目标提供了新的见解.

科学领域:

心血管研究研究心血管研究
分子生物学分子生物学
免疫学免疫学免疫学

背景情况:

急性心肌梗塞 (AMI) 具有重大健康风险.
新兴证据将铜诱导的亡 (cuproptosis) 和免疫细胞透与心血管疾病联系在一起.
在AMI中对cuproptosis生物标志物的研究是有限的,突出显示了关键的知识差距.

研究的目的:

确定和验证急性心肌梗塞 (AMI) 相关的cuproptosis生物标志物.
探索 cuproptosis 和 AMI 中免疫细胞透之间的关系.
根据与cuproptosis相关的基因表达来分类AMI亚型.

主要方法:

对GSE66360数据集的共识聚类,以确定AMI亚型.
差异基因表达分析和Venn图以精确确定与cuproptosis相关的基因.
蛋白质与蛋白质相互作用网络的构建,ROC曲线分析,免疫透的CIBERSORT和转录验证.

主要成果:

确定了两种不同的与cuproptosis相关的AMI亚型,其中有157个不同表达的基因.
五个关键生物标志物得到了验证:大酶A (GZMA),GIMAP7,GIMAP5,GIMAP6和TRAF3IP3.
在AMI中观察到显著的免疫细胞透差异,GZMA与巨细胞和CD8+T细胞相关.

结论:

格兰酶A (GZMA),GIMAP7,GIMAP5,GIMAP6和TRAF3IP3被确定为AMI的新型cuproptosis相关生物标志物.
这些生物标志物在AMI患者的表达有所改变,这表明它们的诊断潜力.
这项研究为了解AMI病原体中的cuproptosis以及开发向治疗提供了理论基础.

更多相关视频

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

Author Spotlight: Integrated Multi-Omics Analysis for Unveiling Multicellular Immune Signatures in Clinical Heart Attack Cohorts

Author Spotlight: Integrated Multi-Omics Analysis for Unveiling Multicellular Immune Signatures in Clinical Heart Attack Cohorts

Published on: September 20, 2024

相关概念视频

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...